Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2013 December;55(4) > Panminerva Medica 2013 December;55(4):327-37

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

  PERCUTANEOUS CORONARY AND VASCULAR INTERVENTIONS


Panminerva Medica 2013 December;55(4):327-37

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current state of percutaneous transcatheter mitral valve therapies

Estevez-Loureiro R. 1, Franzen O. 2

1 Interventional Cardiology Unit Division of Cardiology Complejo Asistencial Universitario de Leon Fundación Investigación Sanitaria Leon (FISLeon) Leon, Spain; 2 Interventional Cardiology Unit Department of Cardiology, Rigshospitalet Copenhagen, Denmark


PDF  


Mitral valve regurgitation (MR) is a frequent condition usually associated with heart failure and reduced survival. Surgery remains the gold standard treatment but a significant number of patients are not optimal candidates due to age, comorbidities or poor left ventricular function. In this subgroup of patients transcatheter mitral interventions have emerged as an alternative to offer improvement of symptoms and increase survival. MitraClip ® is the device with the largest clinical experience and it has been demonstrated to provide clinical benefit in selected patients. However, mitral apparatus is a complex scenario and there are several potential targets for improving mitral regurgitation. The aim of this paper was to review the current trnascatheter technology developed to treat MR.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

owfranzen@gmx.de